bodies in the substantia nigra and terminals in the striatum. When comparing young and adult mice, adult mice were more sensitive for dopaminergic degeneration after lactacystin injection that further supports the use of adult mice instead of young when modeling neurodegeneration. Our data showed that lactacystin is useful in modeling various aspects of Parkinson's disease, and taken together, our findings emphasize the role of a protein degradation deficit in Parkinson's disease pathology, and support the use of proteasomal inhibitors as Parkinson's disease models.
Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disease, with an incidence of 1-2% of people over 65 years old. In PD, dopaminergic neurons in the substantia nigra pars compacta (SNc) degenerate, leading to typical clinical findings such as tremor, rigidity, and bradykinesia due to lack of dopamine in the striatum. Common neuropathological findings of PD are insoluble inclusions, Lewy bodies, mainly consisting of an α-synuclein (aSyn) protein (Spillantini et al. 1998) . Although appearance of Lewy bodies is considered a hallmark for PD, it appears that fibrillary forms of aSyn that are formed during the aggregation process are the toxic species and may be associated with neuronal loss in the SNc (Winner et al. 2011) . Current drug therapies are mostly based on dopamine replacement that only relieves the symptoms of PD but are not curative and cannot stop or delay the progress of the disease. Therefore, it is important to develop novel 1 3 drug therapies and drug candidates, and for this, tools for preclinical studies are needed.
The challenge of generating a mouse model of PD is to find a model that would recapitulate all pathophysiological aspects of the disease: gradual dopaminergic neurodegeneration in the nigrostriatal tract, aSyn-containing protein aggregate formation, motor behavioral deficits, and neuroinflammation. Neurotoxin models, 6-OHDA and MPTP, are conventionally used as PD models that show the gradual dopaminergic neurodegeneration and behavioral deficits, but 6-OHDA fails to produce substantial protein accumulation in the brain and MPTP administration induces nonfibrillar aggregate formation only after extended administration (Meredith et al. 2002; Fornai et al. 2005; Jin et al. 2005) . After revealing that non-soluble aSyn is one of the main components of Lewy bodies (Spillantini et al. 1998) it has been of huge interest to study its role in PD, where it indisputably has a role in the pathogenesis. Since toxin models do not easily produce aSyn-rich protein inclusions, several models that are based on either transgenic or viral vector-mediated overexpression of aSyn have been published (Kahle et al. 2001; Matsuoka et al. 2001; Tofaris et al. 2006; St Martin et al. 2007; Ulusoy et al. 2010; Decressac et al. 2012) . Within the models, there is a wide variation of the degree of neuronal degeneration and protein accumulation, and motor behavioral phenotype of these mice is often weak or not present. Very recently, it was shown that when human aSyn is expressed in a mouse carrying normal mouse aSyn, aSyn aggregation is limited compared to overexpressing human aSyn without mouse aSyn homolog (Fares et al. 2016 ). This finding suggests that synuclein homologs reduce aggregation of each other and offers an explanation on why less toxicity is seen in many transgenic models regardless of high expression.
Although aSyn and its neurotoxic species, oligomers (Winner et al. 2011) , have raised lots of interest in PD research, there are also several other proteins that are present in the Lewy bodies such as ubiquitin and other proteasomal proteins pointing to a role of a failure of protein clearance systems in the pathophysiology of neurodegeneration. Protein accumulation and aggregation may be facilitated by disturbances in cellular clearance and processing pathways, such as ubiquitin-proteasome (UPS) and autophagy-lysosome systems (Ebrahimi-Fakhari et al. 2012) . Importantly, UPS dysfunctions have been linked to PD; decreased proteasomal activity has been identified in the SNc of PD patients (McNaught and Jenner 2001; McNaught et al. 2003; Tofaris et al. 2003) , and genetic mutations in an ubiquitin ligase, parkin, have been linked to early-onset Parkinsonism (Kitada et al. 1998) . Various forms of aSyn have also been shown to compromise its own proteasomal clearance, thus promoting its accumulation (Snyder et al. 2003; Pan et al. 2008a; Ebrahimi-Fakhari et al. 2011 ).
Furthermore, aSyn has been shown to inhibit proteasomal function (Ebrahimi-Fakhari et al. 2011 ) and A30P or A53T point-mutated aSyn also inhibits chaperone-mediated autophagy (Cuervo et al. 2004 ), thus inducing their own accumulation and buildup of other proteins. It still remains to be clarified at what point of the aggregate formation process the protein clearance systems start to decline-at the onset or after protein already accumulates.
A more recent approach to model PD in vivo has been to use lactacystin (LC), a selective proteasome inhibitor (Fenteany and Schreiber 1998) . It has been successfully used in rats and mice and it appears that the nigral administration produces a fast-onset PD-like phenotype, including aSyn accumulation, tyrosine hydroxylase (TH) positive cell loss and behavioral deficits (McNaught et al. 2002; Pan et al. 2008b; Lorenc-Koci et al. 2011; Bentea et al. 2015) . Since aging is one of the key predisposing factors to developing PD or other neurodegenerative diseases, we further characterized the nigral LC injection as a mouse PD model using young and adult mice. Furthermore, we wanted to study the neuroinflammatory responses in this model, because they have not been thoroughly investigated in previous models. We have also analyzed the key elements of a PD model: motor behavior, dopamine cell loss, and aSyn accumulation after LC administration. In addition, to further characterizing the model, we studied the expression of gamma-aminobutyric acid (GABA) markers since increase of GABAergic neurotransmission after the decrease in inhibitory dopaminergic neurons has been described in PD models (Salin et al. 2002; Wang et al. 2010 ).
Experimental procedures Chemicals
Chemicals used were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Ethanol was purchased from Altia (Helsinki, Finland). LC was purchased from A.G. Scientific (#L-1147; San Diego, CA, USA) and dissolved in PBS in concentration of 2 mg/ml. LC solution was protected from light.
Animals
Male C57Bl/6RccHsd mice were obtained from Harlan Laboratories. Mice that were 8-9 weeks (young) and 12-14 months (adult) old were used for the experiments. The animals were maintained at 20-22 °C room temperature with 12:12 h light:dark rhythm and had ad libitum access to food and water. The experiments were carried out according to the European Community guidelines for the use of experimental animals and approved by the Finnish National Board of Animal Experiments (ESAVI/198/04.10.07/2014) .
Stereotactic microinjection and drug treatments
The mice were deeply anesthetized (Univentor anaesthesia unit, Zejtun, Malta) with 2-4% isoflurane (Baxter, Deerfield, IL, USA) and placed on a stereotactic frame (Stoelting, Wood Dale, IL, USA) for injection of 2 µg of LC above the SNc. A 1 μl injection of LC was delivered with a 10 μl-microsyringe (World Precision Instruments, Sarasota, FL, USA) connected to an injector (Quintessential stereotaxic injector, Stoelting) at 0.2 μl/min on the right side of the brain to the following coordinates: A/P −3.2; M/L −1.2; D/V −4.3 from the bregma according to (Franklin and Paxinos 1997) , and the needle was left in place for 5 min after injection until it was slowly withdrawn. Mice received subcutaneous buprenorphine 0.05 mg/kg (Temgesic, Reckit Benckiser Healthcare Ltd, Slough, UK) for post-operative pain relief, and lidocaine (Orion Pharma, Espoo, Finland) was used as a local anesthetic during the operation. Number of animals injected was young mice n = 10 LC injected and n = 8 PBS injected (vehicle) for immunohistochemistry and behavioral analysis, and a separate cohort of n = 7 for HPLC analysis; adult mice n = 3 LC injected and n = 4 vehicle injected. Since we wanted to characterize the fast-onset effects of LC injection, and a previous study (Bentea et al. 2015) reported the mice having the most disturbances in their motor behavior 1 week post-injection, the mice were sacrificed on the 10th day post injection.
Cylinder test
The cylinder test to evaluate forelimb use asymmetry was performed as described previously (Schallert et al. 2000) . More specifically, the mice were removed from their home cage and placed in a plexiglass cylinder (diameter 12 cm, height 15 cm) that rested on a clear plastic platform. A video camera was placed directly underneath the cylinder and each mouse was recorded for 5 min, and then returned to its home cage. Animals were scored by an observer blind to the treatments. The number of touches for each ipsilateral, contralateral, and simultaneous paw placement was recorded. The test was done on the 8th day after LC or PBS microinjection. The contralateral paw use preference was calculated using the following equation: (contralateral paw contacts + 0.5 × both paw contacts)/(ipsilateral + contralateral + both paw contacts). The number of animals was eight in vehicle and ten in LC group in young animals, and four in vehicle and three in LC group adult animals.
Horizontal and vertical activity
The horizontal and vertical activity was tested as described in Mijatovic et al. (2007) to evaluate the effect of LC lesion on the spontaneous locomotor activity. Measurement was performed on the 9th day after injection. Mice were placed in transparent cages (25 cm × 25 cm × 15 cm) in the activity monitor measuring infrared beam interruptions (MED Associates, St. Albans, GA, USA). Due the short length of the experiment, no food or water was placed to cages. The measurement was started right after mice were placed in the cages and the data were collected at 15 min intervals for 2 h. The number of animals was eight in vehicle and ten in LC group in young animals, and four in vehicle and three in LC group adult animals.
Tissue dissection
On the 10th day after LC or PBS microinjection, mice were deeply anesthetized with sodium pentobarbital (150 mg/ kg, i.p.) and transcardially perfused first with phosphatebuffered saline (PBS) to remove blood and then with 4% paraformaldehyde (in PBS) to fix the tissue for immunohistochemistry. Brains were removed and immersed in 4% paraformaldehyde overnight to fix the tissue. The brains were then immersed first in 10% sucrose solution (in PBS) for overnight following with 30% sucrose solution, kept in +4 °C until they sank, after which the samples were quickly frozen with isopentane on dry ice and stored at −80 °C until sectioning. Brains were sectioned at 30 µm thickness. Floating sections were stored in −20 °C. For high-pressure liquid chromatograph (HPLC), striatal samples were quickly dissected from fresh brain tissue after PBS perfusion and frozen at −80 °C until homogenization (described in Mijatovic et al. 2011) .
Immunohistochemistry
For the analysis of brain aSyn, glutamic acid decarboxylase 65/67 (GAD), tyrosine hydroxylase (TH), and glial cell markers (glial fibrillary acidic protein; GFAP and ionized calcium binding adapter molecule; Iba1), immunohistochemistry was performed as described in Mijatovic et al. (2007) and Myöhänen et al. (2012) . In brief, the endogenous peroxidase activity was inactivated with 10% methanol and 3% H 2 O 2 in PBS (pH 7.4) for 10 min (not in immunofluorescence staining), and non-specific binding was blocked with 10% normal donkey serum (aSyn, Iba1) (#S30, Millipore, Temencula, CA, USA) or 10% normal goat serum (TH, GAD, GFAP, Iba1, Ubiquitin) (#S-1000, Vector Laboratories, Burlingame, CA, USA) or 10% normal rabbit serum (GFAP-IFL) (#S-5000, Vector Laboratories) in PBS containing 0.5% Triton-X-100. The sections were incubated overnight at room temperature with primary antibodies in 1% normal serum in PBS (see details in Table 1 ) followed by washing with PBS. The sections were then incubated with the following secondary antibodies, depending on primary antibody; donkey anti-sheep HRP conjugated secondary antibody (aSyn) (1:500, #ab6900, Abcam), goat anti-rabbit HRP conjugated secondary antibody (GAD) (1:500, #31460, Thermo Scientific, Rockford, USA), goat anti-rabbit biotinylated secondary antibody (TH, GFAP and Iba1; 1:500, BA1000, Vector Laboratories), goat anti-rabbit Texas Red conjugated (ubiquitin) (1:200, #T-2767, Thermo Scientific), rabbit anti-chicken fluorescein conjugated (GFAP-IFL) (1:300, #31501, Thermo Scientific), or donkey anti-goat Alexa Fluor 488 conjugated (Iba1-IFL) antibodies (1:200, ab150129, Abcam). The signal for TH, GFAP, and Iba1 staining was enhanced with the avidin-biotin complex -method (Vectastain ® ABC kit standard, #PK-4000, Vector Laboratories). The antigenantibody complexes were visualized following incubation with 0.05% 3,3′-diaminobenzidine and 0.03% hydrogen peroxide solution. Finally, the DAB-stained sections were moved to objective glass, dehydrated in alcohol series, and mounted with Depex (BDH, Poole, UK). Fluorescently labeled sections were mounted with Vectashield (H-1200, Vector Laboratories).
Stereological counting and optical density analysis
The number of TH-positive neurons in the SNc was analyzed by a person blinded to the treatment groups. Three sections from each animal were selected (every 6th section). StereoInvestigator (MBF Bioscience, USA) was used for the stereological analysis. TH-positive cells were counted at predetermined intervals (x = 100 μm, y = 80 μm) within the counting frame (60 μm × 60 μm) superimposed on the image using a 60× oil objective (Olympus BX51, Olympus Optical, Japan) equipped with an Optronics camera.
For optical density (OD) analysis of aSyn, TH, and GAD, immunohistochemically stained brain sections were imaged using 3DHISTECH slide scanner (3DHISTECH Ltd., Budabest, Hungary) at the service provided in the Institute of Biotechnology, University of Helsinki. ODs were analyzed using ImageJ (NIH, Bethesda, MD, USA). Images were converted into grayscale and inverted before analysis. Area to be analyzed was selected using the freehand selection tool. The background staining values of each brain area were subtracted from raw data values of the same brain area.
Neuroinflammation in the brain was semi-quantitatively analyzed using Image Pro Plus 6 software (Media Cybernetics, Rockville, MD, USA). Briefly, images of brain sections that were exported from 3DHISTECH were converted into grayscale and inverted. Then predetermined area was analyzed from the substantia nigra (SN) injection side and control side. To estimate area stained in the striatum, a circular annotation was drawn over the area and same sized regions were analyzed from both sides. Areas stained in the selected regions were counted using count and measure objects tool. Number of animals in aSyn, TH, and GAD analysis was four in vehicle group and eight in LC group (young) and four in vehicle and three in LC group (adult). In glial cell markers, the number of animals was three in vehicle and three in LC group in both age groups. Altogether 3-4 samples of each brain area/staining per animal per group were analyzed. OD values for each mouse were calculated as OD injection side/OD intact side × 100%. Image panels were prepared by Adobe Photoshop CS6 software (version 13.0, Adobe Systems, San Jose, CA, USA).
Confocal microscopy
Fluorescent double-labeled sections were photographed using an upright microscope (Leica DM5000B, Leica Microsystems Inc.) with broadband laser confocal device (Leica TCS SP5, Leica Microsystems Inc.). After the images were captured with an imaging device, confocal double-labeled immunofluorescence micrographs were merged to detect colocalization using Adobe Photoshop CS6 software (Adobe Systems). Only corrections to brightness and contrast were made.
Analysis of neurotransmitters and metabolites
The striatal brain tissue samples were homogenized as described earlier (Airavaara et al. 2006) . Briefly, the striatal samples were homogenized in 0.5 ml of homogenization solution (0.2 M HClO 4 and antioxidant solution). The homogenates were centrifuged at 20,800g for 35 min at 4 °C. Supernatant was removed to 0.5 ml Vivaspin filter concentrators (10,000 MWCO PES; Vivascience AG, Hannover, Germany) and centrifuged at 8600g at 4 °C for 35 min. The tissue concentrations of dopamine, its main metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) were analyzed with a HPLC equipped with an electrochemical detector. Concentrations are calculated as nanograms per milligram of brain tissue. Number of animals was seven in both treatment groups.
Statistics
Statistical analysis was done using GraphPad Prism 5 and 6 softwares. Student's t test, one-way ANOVA with Newman-Keuls multiple comparisons or two-way ANOVA with Tukey's multiple comparisons test were used. Data are presented as mean ± SEM and F values are included with statistics.
Results

Motor impairment after LC administration
To evaluate the degree of LC-induced unilateral lesion in the nigrostriatal tract, we measured horizontal and vertical locomotor activity as well as assessed the ipsilateral and contralateral limb use with cylinder test in mice. Additionally, we observed spontaneous contralateral rotating behavior in LC-injected mice of both age groups starting and being the strongest 2-3 days after the injection and continuing to the end of the experiment but this was not quantitatively analyzed.
Cylinder test
The paw use preference during rearing was measured with cylinder test. LC groups had reduced use of contralateral paw 8 days after lesioning pointing to unilateral damage of nigrostriatal tract ( Fig. 1e, f ; t = 2.751, df = 16; P = 0.0142 and adult: t = 2.390, df = 5; P = 0.0624, Student's t test).
Horizontal and vertical activity
Locomotor activity was measured for 2 h on the 9th day after LC lesioning. LC showed a trend to reduce total distance traveled ( Fig. 1a ; young: t = 1.776; df = 16; P = 0.0948, Student's t test) and vertical counts ( Fig. 1b ; t = 1.941, df = 16; P = 0.0701, Student's t test) in young mice. In adult animals, there were no alterations in distance traveled or vertical activity, although the trend in distance traveled was opposite to young mice ( Fig. 1c,  d ; t = 0.9442, df = 5; P = 0.3884 and t = 0.047, df = 5; P = 0.9643, respectively, Student's t test). However, the number of animals in adult mice groups (3 and 4) is not sufficient to achieve statistically reliable results in behavioral tests, and therefore, these results cannot be considered conclusive.
Reduction of markers of nigrostriatal dopamine system after LC injection
In the SNc, LC induced approx. 40% TH-positive neuron loss in young mice and 50% decrease in adult mice ( Fig. 2d-f ; Young: t = 3.432, df = 10; P = 0.0064; Fig. 2j-l ; adult: t = 2.358, df = 5; P = 0.0649). TH-positive neurons remaining in the LC-lesioned side compared to the unlesioned side of the SNc were 64.9 ± 5.4% in the young and 62.6 ± 15.52 in the adult mice (Fig. 2f, l) . LC significantly decreased striatal TH OD ( Fig. 2a-c ; young: t = 4.412, df = 9; P = 0.0017; Fig. 2g , h; adult: t = 3.620, df = 5; P = 0.0152, Student's t test) and TH loss was significantly greater in the adult mice; the remaining amount of TH-positive terminals in the lesion side compared to control side was 61.39 ± 10.7% in adult and 80.1 ± 2.8% in young mice (Fig. 2c, i) . This was also observed in two-way ANOVA analysis (Fig. 2m) where LC had a significant effect on striatal TH (P < 0.0001; F(1, 14) = 33.76, two-way ANOVA), and there was also an interaction with the age of the mice (P = 0.0432; F(1, 14) = 4.944, interaction (LC × age), two-way ANOVA).
Striatal dopamine levels were measured only from the young mice after LC lesion. LC injection above the SN decreased the level of striatal dopamine by approximately 55% ( Fig. 2n ; t = 3.581, df = 12; P = 0.0038) and its metabolite DOPAC ( Fig. 2n ; t = 2.737, df = 12; P = 0.0180) compared to intact side. The levels of HVA were not significantly altered ( Fig. 2n ; t = 0.5983, df = 12; P = 0.5608). LC did not affect 5-HT or 5-HIAA levels (see supplementary materials S1).
LC-induced glial cell activation and accumulation of ubiquitinated proteins in glial cells
Lactacystin induced strong and widespread astroglial cell activation. Intense GFAP immunoreactivity was seen throughout the whole injected hemisphere at the SN level (anterior-posterior) after lactacystin injection compared to PBS and to uninjected side (Fig. 3a , b, q, P = 0.0003; F(3, 11) = 23.20, P < 0.001 Newman-Keuls post hoc test, one-way ANOVA). Lactacystin also increased the expression of ubiquitinated proteins in GFAP-positive cells that were not seen in such high amounts in the control side (Fig. 4a-l) or after PBS injection ( Supplementary  Fig. S2 ). Although we saw an increased GFAP activation around the lactacystin-injected brain hemisphere in adult mice (Fig. 3c, d ), due to large variance in our small sample group, the data did not reach significance in the statistical assay. Moreover, astroglial activation was also seen in the striatum, particularly in adult mice (Fig. 3e , f, r; young: lactacystin vs. PBS; P = 0.0150; F(3, 11) = 6.563, P < 0.01, intact vs. lactacystin; P < 0.05; adult: lactacystin vs. PBS; P = 0.0054; F(3, 11) = 9.378, P < 0.01 Newman-Keuls post hoc test, one-way ANOVA) but not in the cortical brain structures of the injected side.
In addition to astroglial activation, microglial cells detected by Iba1 were intensively activated in the SN level after LC injection (Fig. 3i-j, s; young: intact vs. LC; Fig. 1 a-f The behavioral assessment of mice after unilateral nigral lactacystin (LC) lesioning by cylinder and locomotor activity tests. The paw use preference for rearing 8 days after LC injection was measured by cylinder test. Both LC groups showed decreased use of contralateral paw (young mice: P = 0.0142) although insignificantly in adult mice (ns, P = 0.0624) (a, b). Horizontal and vertical activity was measured for 2 h 9 days after LC (2 µg) injection. Stereotactic injection of PBS was used as a sham control. In young, 8-9 weeks old mice, LC shows a trend to decrease total distance traveled (ns, P = 0.0948) (c) and vertical counts (ns, P = 0.0701) (d). In adult mice, no effect was seen in the locomotor activity (e, f). *P < 0.05; unpaired Student's t test was used as statistical analysis in all experiments; n = 10 LC injected and 8 vehicle in young mice, n = 3 LC injected and 4 vehicle in adult mice Fig. 2 a-n Tyrosine hydroxylase (TH) positive neuron loss and reduced striatal dopamine (DA) and metabolite content after lactacystin (LC) lesion. LC administered supranigrally significantly decreased TH optical density (OD) in the striatum of young (8-9 weeks old, a-c), and in the striatum of adult mice (12-14 months old, g-i) . The interaction between striatal TH decrease and age and LC injection was also observed in two-way ANOVA analysis (m; P < 0.0001 LC; P = 0.0432 interaction (age × LC), two-way ANOVA). In the substantia nigra pars compacta (SNc), the cell loss was at the same level in both age groups (young d-f; adult j-l, P = 0.06 in adult mice). In the young mice, 10 days after LC injection, significant depletion of the striatal DA (n) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels was observed. However, no significant decrease was seen in the homovanillic acid (HVA) levels. *P < 0.05, **P < 0.01; unpaired Student's t test was used as statistical analysis in all experiments; n = 8 LC injected and 4 vehicle in young mice, n = 3 LC injected and 4 vehicle in adult mice; n = 7 in both groups in HPLC assays P = 0.0002; F(1, 8) = 39.88, P < 0.01; Fig. 3k , l, v; adult: LC vs. PBS P = 0.0014, F(1, 8) = 22.56, P < 0.01, intact vs. LC P = 0.0092; F(1, 8) = 11.64, P < 0.01 Tukey's post hoc test, two-way ANOVA). Similar to astroglial cells, microglial cell activation was widespread, covering the whole LC-injected brain hemisphere at the level of injection (anterior-posterior) in both young and adult mice (Fig. 3m-p) . In addition, similar accumulation of ubiquitinated proteins as in GFAP-positive astroglial cells were seen in microglial cells in double-label immunofluorescence (Fig. 4m-x) . No difference in activation of microglial cells was observed in the striatum.
LC induces aSyn accumulation in the substantia nigra
LC produced robust accumulation of aSyn in the SN compared to PBS control group (Fig. 5a -c, e-g; young: df = 14; P = 0.0012; adult: t = 3.161, df = 5; P = 0.0251, Student's t test). Accumulation percentages for young mice are 105.4 ± 5.1 for PBS, 169.3 ± 20 for LC and for adult mice 104.8 ± 16.9 vs. 185.7 ± 19.2 (Fig. 5c, g ). The accumulation was observed both in the SNc and SN pars reticulata (SNr). We did not observe a significant increase of aSyn in the striatum after LC (Fig. 5d, h ).
LC induces increase in GAD in SNr
As we observed aSyn accumulation in the SNr, we also wanted to study the expression of GAD, a GABA synthesizing enzyme. We saw accumulation of GAD in the SNr after LC lesioning in young mice 142.3 ± 6.6% compared to PBS control 103.8 ± 2.1% and in adult mice 150 ± 8.5% compared to 98.5 ± 5.9% (Fig. 6a-c , young: t = 5.094, df = 14; P = 0.0001; Fig. 6d-f , adult: t = 5.180, df = 5; P = 0.0035; Student's t test).
Discussion
In this study, we have characterized a mouse model of PD that is based on direct proteasomal inhibition in the SN of young and adult mice. Although LC has been used as a PD model in earlier studies either by injecting it into the medial forebrain bundle or striatum (Fornai et al. 2003; Vernon et al. 2011; Shen et al. 2013; Konieczny et al. 2014a) , and recently in mouse (Bentea et al. 2015; Kumar et al. 2015) and rat (Konieczny et al. 2014b; Harrison et al. 2015; Pienaar et al. 2015 ) SN, to our knowledge this is the first time when LC injection has also been used in adult mice and widespread neuroinflammation has been observed and thoroughly analyzed. The model shows several well-established features of PD-motor deficits, nigrostriatal dopamine loss, and aSyn accumulation as the most important, and we indeed detected differences in response between young and adult mice. However, the number of adult mice in the current study was low and this should be kept in mind when drawing conclusions based on our results.
Young LC-injected mice showed hypolocomotion in 2 h locomotor activity test and both age groups had a tendency to use more ipsilateral paw in cylinder test, indicating a deficit of nigrostriatal dopaminergic system. In mice, LC injection in medial forebrain bundle (MFB) or SN has been shown to rapidly induce motor behavioral decline (Li et al. 2010; Bentea et al. 2015) , and similarly in rats, motor decline has been reported after MFB or SN injection (Vernon et al. 2011; Konieczny et al. 2014a) . Interestingly, striatal injection of LC in rats did not cause behavioral decline in a study by Lorenc-Koci et al. (2011) .
LC rapidly produced dopaminergic neurodegeneration in SN and depletion of striatal dopamine levels leading to motor behavioral deficits, which is an important aspect for a PD model. Our observations are similar to previous studies (Vernon et al. 2011; Bentea et al. 2015) which showed the maximal neurodegenerative effect of LC at one week after injection. In our study, significant TH-positive cell loss was observed in SNc, but in our 10-day study, the lesion did not markedly proceed to the striatum in the young mice when TH-positive terminals were analyzed. However, striatal dopamine and DOPAC levels were reduced by 55%, suggesting that dopamine synthesis is decreased, although the TH protein is still present. This may suggest that TH has been inhibited or neuronal damage is still progressing at day 10, although in another study striatal dopamine and DOPAC levels did not decrease any further after 1 week (Bentea et al. 2015) . However, the dose of LC may explain this difference; Bentea et al. used a 3 µg dose in mice, whereas in our studies the dose was 2 µg; it is possible that with a lower dose, the neuronal degeneration is still progressing. Slow progression of LC-induced pathology has also been reported by Harrison et al. (2016) where they noticed a decrease in TH-positive neurons of the ventral Fig. 3 a-v The effects of lactacystin (LC) on GFAP and Iba1 immunoreactivity. LC microinjection above the substantia nigra induced widespread activation of astroglial cells around the hemisphere of injection side at nigral level, that were detected by glial fibrillary acidic protein (GFAP) staining (young, a, b, q; adult, c, d, t) . GFAP immunostaining was also seen in the striatum after LC injection and it was particularly intense in adult mice (young, e, f, r; adult, g, h, u). Similar to GFAP, microglial cells were significantly activated in LC injected side (ionized calcium binding adapter molecule (Iba1);  young, i, j, m, n, s; adult, k, l, o, p, v) . Young mice 8-9 weeks old, adult mice 12-14 months old. Scale bar 100 µm. *P < 0.05, **P < 0.01, P < 0.001, vs. intact, # P < 0.05, ## P < 0.01, ### P < 0.001 vs. PBS injection; GFAP: Newman-Keuls post hoc test, one-way ANOVA; Iba1: Tukeys's post hoc test, two-way ANOVA; n = 3 in all groups ◂ Fig. 4 a-x Accumulation of ubiquitin-labeled proteins in astroglial and microglial cells after lactacystin injection. Ubiquitin-immunostained (UbiQ) cells were generally decreased in LC injected side of the substantia nigra (b, n) compared to intact side (e, q). Increased colocalization between UbiQ and GFAP was seen after LC injection (g-i), and similar staining was seen between UbiQ and Iba1 (s-u). In intact side, less colocalization was seen with UbiQ both in GFAP and Iba1-labeled cells (j-l, v-x). White arrows are pointing to the colocalization. Scale bar 50 µm in a-f and m-r, and 5 µm in g-l and s-x Fig. 5 a- h Accumulation of α-synuclein (aSyn) in SN after lactacystin (LC) injection. Representative images of nigral aSyn immunostaining 10 days after nigral stereotaxic injection of PBS and LC in young (a, b) and adult (e, f) mouse. LC produced robust accumulation of aSyn in the substantia nigra (SN) compared to PBS control group (young mouse; c, P < 0.01; adult mouse; g, P < 0.05) However, significant accumulation of aSyn in the striatum was not detected in both groups (d, h). *P < 0.05, **P < 0.01, unpaired Student's t test; n = 8 LC injected and 8 vehicle in young mice, n = 3 LC injected and 4 vehicle in adult mice tegmental area 5 weeks after LC injection. Moreover, aSyn is known to inhibit TH activity (Perez et al. 2002; Lou et al. 2010 ), and we observed increased aSyn levels in the SN, suggesting a mechanism for reduced dopamine content in the striatum. When we investigated striatal TH ODs in young and adult mice, the TH loss seems to be greater in the adult mice, which supports the role of age as a factor for neurodegeneration. Although the number of adult mice was low in our study, the results suggest that it might increase the validity and translation of the results where the preclinical studies would be made in age-matched animals. Dopaminergic neurotransmission inhibits the GABAergic system, and when dopaminergic regulation is decreased in PD, GABAergic neurotransmission is enhanced (for review, see Galvan and Wichmann 2007) . As presumed, in our study GAD expression was elevated in SNr, possibly contributing to a decrease of striatal dopamine. Increased GAD expression is also seen in earlier neurotoxin studies, where increased GABAergic activity (Wang et al. 2010 ) and GAD mRNA expression (Salin et al. 2002; Wang et al. 2010) in the lesion side in PD 6-OHDA rat model has been reported. In addition, LC is not a specific toxin for dopaminergic neurons, and increase in GAD may also propose that dopaminergic neurons are more sensitive for LC toxicity than GABAergic neurons in SN.
Interestingly, we observed massive glial cell activation after LC injection. Glial activation is characteristic for PD and other synucleinopathies (McGeer et al. 1988; Gerhard et al. 2003; Braak et al. 2007; Stefanova et al. 2007; Iannaccone et al. 2013) . Both astroglial and microglial cells were activated throughout the LC-injected hemisphere and this indicates that LC, and possibly also increased aSyn protein accumulation, has activated a pro-inflammatory signal cascade leading to widespread activation of glial cells that may further enhance the neurodegeneration (Imamura et al. 2003; Gao et al. 2008; Kwon et al. 2008; Lee et al. 2010) . Glial activation in the SN in the LC model has earlier been reported in mice (Li et al. 2010) but in the rat model no remarkable activation three weeks after injection was seen (McNaught et al. 2002) . However, in the studies by Pienaar et al. (2015) and Elson et al. (2016) , LC injection to rat SN caused significantly increased microglial cell activation in pedunculopontine nucleus that was accompanied by increased aSyn expression, supporting the spreading of aSyn pathology and glial activation after proteasome inhibition.
Proteasome inhibition has been shown to inhibit GFAP expression (Middeldorp et al. 2009 ) and despite the widespread astrogliosis, we saw reduced GFAP immunostaining around the injection site in the SN indicating that astrogliosis is a result of activated inflammatory cascades, not only spread of the 1 μl volume. Unfortunately, we are not able to directly compare a difference in the amount of activation of neuroinflammation in the two age groups of mice because they were not stained and sections were not scanned simultaneously. However, based on immunostaining, more intense spreading of astrogliosis to striatum was seen in adult mice, suggesting that their nigrostriatal tract is more vulnerable for glial activation. In addition to glial activation, we also detected increased ubiquitin-positive immunostaining in astroglial and microglial cells after LC injection. Astroglial cells are also responsive for proteasomal deficits and develop protein aggregates but they are not as sensitive as neurons (Goldbaum et al. 2009 ) and usually protein aggregates are less abundant than in neurons Fig. 6 a-f Accumulation of glutamic acid decarboxylase 65/67 (GAD) in the SN pars reticulata (SNr) after lactacystin (LC) lesioning. In both age groups [young 8-9 weeks old (a-c), adult 12-14 months old (d-f)] significant accumulation GABA synthesizing enzyme, GAD, was observed compared to sham lesion control (young mouse; c, P < 0.001; adult mouse; f, P < 0.01). **P < 0.01, ***P < 0.001, unpaired Student's t test; n = 8 LC injected and 8 vehicle in young mice, n = 3 LC injected and 4 vehicle in adult mice (Wakabayashi et al. 2000; Braak et al. 2007 ). However, proteasomal inhibition can disrupt glial cells (Kwon et al. 2008; Middeldorp et al. 2009 ) leading to their dysfunction that further enhances neurodegeneration. aSyn can also be directly transferred from neurons to astroglia which leads to formation of inclusion bodies and activation of microglia by cytokines and chemokines (Lee et al. 2010) . Our results further support this finding.
Important for mimicking PD pathology, we observed increased aSyn immunostaining in the SN, supporting the role of proteasomes in aSyn accumulation and also the toxicity of aSyn to dopaminergic neurons. Recent studies have shown accumulation of phosphorylated aSyn in mice SN after LC injection (Bentea et al. 2015) in immunohistochemistry but also reduced soluble aSyn has been observed in rat (Lorenc-Koci et al. 2011) in Western blot. Although Lorenc-Koci et al. (2011) did not measure the oligomeric forms of aSyn, the toxic species, it is likely that disturbed degradation of aSyn by blocking the proteasomes lead to increased concentration of aSyn which is a key factor to enhance the interaction between aSyn molecules, leading to aggregation of aSyn (Wood 1999) . It remains a challenge to study aSyn protein aggregation in a mouse that does not have transgenic human aSyn, since there is a lack of decent and specific antibodies against mouse oligomeric or phosphorylated aSyn.
Conclusions
In this study, we characterized various aspects of LC administration as a preclinical PD model and focused on studying the early changes (less than 2 weeks) occurring after injection. The presented LC mouse model very well establishes PD-like characteristics with motor disturbances, degeneration of TH-positive neurons with dopamine loss, aSyn accumulation, and neuroinflammation. In addition, although the number of adult mice in this study was low, our results suggest that older mice were more sensitive for dopaminergic cell loss compared to young animals, supporting their use in the PD toxin models. In longer term studies, it might be rational to scale down the dose to observe a milder and progressive phenotype and to study the effects in human aSyn expressing/overexpressing animals. Furthermore, it remains to be studied what would be the long-term effects of LC in terms of aSyn aggregate formation and possible recovery. This model is an interesting preclinical tool to be used for studying many types of treatment strategies against PD and also other diseases associated with protein clearance deficits and neuronal inflammation.
